ROS1 and neoplasm: In the PROFILE 1001 trial, crizotinib efficacy was independent of ROS1 translocation type.14 A retrospective analysis showed that patients whose tumor harboring CD74-ROS1 had a significantly shorter median PFS with first-line crizotinib than those harboring non-CD74-ROS1 fusions27 (17.0 months vs. 21.0 months; P = 0.008).